Monday, 8 December 2014: 15:35 - 15:55
Sala A (Sul America)
Kenji Izuhara, MD, PhD
,
Division of Medical Biochemistry, Department of Biomolecular Sciences,, Saga Medical School, Japan
Learning Objectives:
It is now widely accepted that bronchial asthma is not a single disease and that bronchial asthma is a syndrome encompassing several disease entities. It is important to discriminate asthma patients into several asthma endotypes defined by distinct pathophysiologocal mechanisms for choosing appropriate therapies and drugs. Serum periostin has recently emerged as a potentially useful biomarker for categorization of asthma endotypes and subsequently for prediction of the efficacy of molecular target drugs against bronchial asthma such as anti-IL-13 antibody and anti-IgE antibody. Since we previously found periostin as a downstream molecule of IL-13, a type 2 signature cytokine, it is plausible that serum periostin reflects the status of type 2 immune response in asthma patients. Moreover, serum periostin is a biomarker reflecting the remodeling of bronchial tissues including fibrosis in asthma. Based on this notion, we found that serum periostin is correlated with steroid-insensitivity particularly in the eosinophil-dominant and late onset type of asthma patients. In this lecture, I am going to summarize the history of the analyses of periostin and show our latest results regarding with periostin in the field of bronchial asthma.
It is now widely accepted that bronchial asthma is not a single disease and that bronchial asthma is a syndrome encompassing several disease entities. It is important to discriminate asthma patients into several asthma endotypes defined by distinct pathophysiologocal mechanisms for choosing appropriate therapies and drugs. Serum periostin has recently emerged as a potentially useful biomarker for categorization of asthma endotypes and subsequently for prediction of the efficacy of molecular target drugs against bronchial asthma such as anti-IL-13 antibody and anti-IgE antibody. Since we previously found periostin as a downstream molecule of IL-13, a type 2 signature cytokine, it is plausible that serum periostin reflects the status of type 2 immune response in asthma patients. Moreover, serum periostin is a biomarker reflecting the remodeling of bronchial tissues including fibrosis in asthma. Based on this notion, we found that serum periostin is correlated with steroid-insensitivity particularly in the eosinophil-dominant and late onset type of asthma patients. In this lecture, I am going to summarize the history of the analyses of periostin and show our latest results regarding with periostin in the field of bronchial asthma.